JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on August 24, 2005; DOI: 10.1124/jpet.105.091017


0022-3565/05/3153-1150-1157$20.00
JPET 315:1150-1157, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.105.091017v1
315/3/1150    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hansen, P. B.
Right arrow Articles by Schnermann, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hansen, P. B.
Right arrow Articles by Schnermann, J.

GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Vasoconstrictor and Vasodilator Effects of Adenosine in the Mouse Kidney due to Preferential Activation of A1 or A2 Adenosine Receptors

P. B. Hansen, S. Hashimoto, M. Oppermann, Y. Huang, J. P. Briggs, and J. Schnermann

National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland

The present experiments in mice were performed to determine the steady-state effects of exogenous adenosine on the vascular resistance of the whole kidney, of superficial blood vessels, and of afferent arterioles. The steady-state effect of an intravenous infusion of adenosine (5, 10, and 20 µg/min) in wild-type mice was vasodilatation as evidenced by significant reductions of renal and superficial vascular resistance. Resistance decreases were augmented in adenosine 1 receptor (A1AR) –/– mice. Renal vasodilatation by the A2aAR agonist CGS 21680A [2-p-(2-carboxyethyl)phenethyl-amino-5'-N-ethylcarboxamido-adenosine hydrochloride] (0.25, 0.5, and 1 µg/kg/min) and inhibition of adenosine-induced relaxation by the A2aAR antagonist ZM-241385 [4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-yl-amino]ethyl)phenol] (20 mg/kg) suggests that the reduction of renovascular resistance was largely mediated by A2aAR. After treatment with N{omega}-nitro-L-arginine methyl ester (L-NAME) adenosine was unable to alter superficial blood flow and resistance significantly indicating that adenosine-induced dilatation is NO-dependent. Absence of a dilatory effect in endothelial nitric-oxide synthase (NOS) –/– mice suggests endothelial NOS as the source of NO. When infused into the subcapsular interstitium, adenosine reduced superficial blood flow through A1AR activation. Adenosine (10–7 M) constricted isolated perfused afferent arterioles when added to the bath but not when added to the luminal perfusate. Luminal adenosine caused vasoconstriction in the presence of L-NAME or the A2AR antagonist 3,7-dimethyl-1-(2-propynyl)xanthine. Our data show that global elevation of renal adenosine causes steady-state vasorelaxation resulting from adenosine 2 receptor (A2AR)-mediated generation of NO. In contrast, selective augmentation of adenosine around afferent arterioles causes persistent vasoconstriction, indicating A1AR dominance. Thus, adenosine is a renal constrictor only when it can interact with afferent arteriolar A1AR without affecting the bulk of renal A2AR at the same time.


Received for publication June 14, 2005
Accepted August 19, 2005.

Address correspondence to: Dr. Jurgen Schnermann, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bldg. 10, Room 4 D51, 10 Center Dr., MSC 1370, Bethesda, MD 20892. E-mail: jurgens{at}intra.niddk.nih.gov




This article has been cited by other articles:


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M. Carlstrom, E. Y. Lai, Z. Ma, A. Patzak, R. D. Brown, and A. E. G. Persson
Role of NOX2 in the regulation of afferent arteriole responsiveness
Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2009; 296(1): R72 - R79.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
A. Patzak, A. Steege, E. Y. Lai, J. O. Brinkmann, E. Kupsch, N. Spielmann, A. Gericke, A. Skalweit, J. Stegbauer, P. B. Persson, et al.
Angiotensin II response in afferent arterioles of mice lacking either the endothelial or neuronal isoform of nitric oxide synthase
Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2008; 294(2): R429 - R437.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
A. Patzak, E. Y. Lai, M. Fahling, M. Sendeski, P. Martinka, P. B. Persson, and A. E. G. Persson
Adenosine enhances long term the contractile response to angiotensin II in afferent arterioles
Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2007; 293(6): R2232 - R2242.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M.-G. Feng and L. G. Navar
Adenosine A2 Receptor Activation Attenuates Afferent Arteriolar Autoregulation During Adenosine Receptor Saturation in Rats
Hypertension, October 1, 2007; 50(4): 744 - 749.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
Z. Guan, D. A. Osmond, and E. W. Inscho
Purinoceptors in the Kidney
Experimental Biology and Medicine, June 1, 2007; 232(6): 715 - 726.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.